The significance of early treatment of exudative age-related macular degeneration: 12 months' results

Wien Klin Wochenschr. 2012 Nov;124(21-22):750-5. doi: 10.1007/s00508-012-0249-3. Epub 2012 Oct 24.


Background: To assess whether the period between initial symptoms and therapy with ranibizumab in patients with choroidal neovascularization (CNV) influences visual outcome after a follow-up of 12 months.

Methods: Fifty patients with CNV were retrospectively split into three groups depending on the duration of visual symptoms: group I: < 1 month, group II: 1-6 months, and group III: > 6 months. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded at baseline, 2, 6, and 12 months. Patients received two initial intravitreal injections of 0.5 mg ranibizumab at baseline and reinjections as needed.

Results: The mean time span between initial symptoms and treatment was 66 ± 63 days. A longer duration of visual symptoms was significantly correlated with a lower BCVA at baseline, but also after 6 and 12 months.

Conclusions: Shorter duration of visual symptoms prior to treatment is associated with a better visual outcome.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Choroidal Neovascularization / complications
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / drug therapy*
  • Female
  • Humans
  • Macular Degeneration / complications
  • Macular Degeneration / diagnosis
  • Macular Degeneration / drug therapy*
  • Male
  • Ranibizumab
  • Secondary Prevention / methods
  • Treatment Outcome
  • Vision Disorders / diagnosis
  • Vision Disorders / etiology
  • Vision Disorders / prevention & control*


  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Ranibizumab